PHILADELPHIA, Pennsylvania, April 2026
Century Therapeutics announced that its investigational program CNTY-813 has been selected for oral presentation at the American Diabetes Association (ADA) 86th Scientific Sessions, showcasing promising preclinical data in autoimmune disease targeting. The therapy is part of the company’s advanced iPSC-derived cell therapy platform, designed to deliver off-the-shelf, engineered immune cell treatments with improved precision and scalability. The presentation underscores growing momentum behind cell-based immunotherapies beyond oncology, particularly in chronic diseases such as type 1 diabetes, where durable immune modulation remains a critical unmet need.
CNTY-813 Demonstrates Targeted Immune Modulation Potential
The preclinical data highlight CNTY-813’s ability to selectively target disease-driving immune pathways, supporting its potential as a next-generation cell therapy for autoimmune disorders. Built using induced pluripotent stem cell (iPSC) technology, the therapy is engineered to deliver controlled and sustained immune responses, overcoming limitations of traditional autologous therapies such as variability, manufacturing complexity, and high costs.
The platform enables consistent product quality and scalable manufacturing, which are essential for broader clinical adoption. Early findings suggest that CNTY-813 may provide durable immune regulation, a key factor in diseases like type 1 diabetes where immune system dysfunction leads to progressive tissue damage.
Advancing Off-the-Shelf Cell Therapy Innovation
Advertisement
Century Therapeutics continues to position itself at the forefront of allogeneic cell therapy development, leveraging its proprietary platform to create readily available, standardized treatments. Unlike patient-specific therapies, CNTY-813 is designed as an off-the-shelf product, significantly reducing treatment timelines and expanding patient access.
The selection for oral presentation at a major scientific forum such as ADA highlights the scientific relevance and translational potential of the program. This also reflects increasing industry focus on expanding cell therapy applications beyond cancer into broader immunological diseases, where precision immune modulation can transform long-term disease management.
Expanding the Role of Cell Therapy in Autoimmune Diseases
The inclusion of CNTY-813 at ADA 2026 signals a broader shift in therapeutic strategy, where engineered immune cells are being explored as disease-modifying treatments rather than symptomatic solutions. By directly addressing the underlying immune dysfunction, therapies like CNTY-813 aim to alter disease progression rather than manage symptoms, offering potential long-term benefits. As the field evolves, scalable, off-the-shelf cell therapies are expected to play a critical role in reshaping treatment paradigms across multiple autoimmune indications.
This development reinforces Century Therapeutics’ commitment to advancing innovative, cell-based therapeutics and highlights the growing convergence of stem cell biology, immunology, and precision medicine in next-generation drug development.
Source: Century Therapeutics press release
